Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Price analytics
Returns
1 day
0.0%
1 week
-40.0%
1 month
-72.7%
3 months
-94.5%
6 months
-97.0%
1 year
-99.0%
3 years
-99.9%
Risk
Volatility (1y ann.)
291.4%
Beta vs ASX 200
-1.52
Sharpe (1y)
-0.31
VaR 95% (1-day)
-25.0%
Max drawdown (1y)
-99.3%
Off 1-year high
-99.3%
Technicals
RSI(14)
30
OS
vs 50DMA
-84.3%
vs 200DMA
-97.6%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value100.0
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
100
Growth—
Revenue growth (1y)
—
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow)34.8
Return on equity
—
Return on assets
0
Operating margin
100
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum0.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
0
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).